Rui-hua H. Xu
651 Dongfeng East Road
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 127 publications
Author Correction: A circRNA signature predicts postoperative recurrence in stage II/III colon cancer.
Journal: EMBO molecular medicine
Published: August 10, 2026
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.
Journal: Journal of hematology & oncology
Published: April 26, 2026
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 19, 2026
Announcing the Lancet Commission on colorectal cancer: addressing the rising global burden.
Journal: Lancet (London, England)
Published: February 05, 2026
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).
Journal: Journal of hematology & oncology
Published: February 02, 2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancer.
Journal: Gut
Published: September 15, 2025
Corrigendum to "Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance" [Cancer Lett. (2018) 412 243-255].
Journal: Cancer letters
Published: August 20, 2025
Last Updated: 09/26/2026